8-K
filed February 2, 2023, 6:59 PM ET
ticker MRK
CIK 0000310158
earnings
confidence high
sentiment neutral
materiality 0.75
Merck Q4 GAAP EPS $1.18, revenue $13.8B; guides FY2023 non-GAAP EPS $6.80-$6.95
Merck & Co., Inc.
2022-FY EPS reported
$5.71
revenue$59,283,000,000
- Q4 2022 GAAP EPS $1.18 (down 22% YoY); non-GAAP EPS $1.62 (down 10%); revenue $13.8B (+2%, +8% ex-FX).
- Full-year 2022 sales $59.3B (+22% YoY); KEYTRUDA $20.9B (+22%); GARDASIL $6.9B (+22%).
- FY2023 guidance: sales $57.2B-$58.7B (incl. ~$1B LAGEVRIO); GAAP EPS $5.86-$6.01; non-GAAP EPS $6.80-$6.95.
- Completed Imago BioSciences acquisition for $1.35B; new ADC collaboration with Kelun-Biotech.
- Regulatory: KEYTRUDA approved for adjuvant NSCLC; positive KEYNOTE-859 (gastric) and KEYNOTE-966 (biliary) data.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Merck & Co., Inc. reported Fourth-Quarter 2022 results: revenue $13.8 Billion, EPS $1.18; $1.62. Guidance initiated.
- Period
- Fourth-Quarter 2022
- Revenue
- $13.8 Billion
- EPS
- $1.18; $1.62
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Fourth-Quarter 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2% From Fourth Quarter 2021; Growth Excluding the Impact of Foreign Exchange Was 8% - Fourth-Quarter 2022 GAAP EPS From Continuing Operations Was $1.18; Fourth-Quarter 2022 Non-GAAP EPS Was $1.62
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
Merck & Co., Inc. reported Full-Year 2022 results: revenue $59.3 Billion, EPS $5.71; $7.48. Guidance initiated.
- Period
- Full-Year 2022
- Revenue
- $59.3 Billion
- EPS
- $5.71; $7.48
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
Full-Year 2022 Worldwide Sales Were $59.3 Billion, an Increase of 22% From Full Year 2021; Growth Excluding LAGEVRIO Was 12%; Growth Excluding LAGEVRIO and the Impact of Foreign Exchange Was 15% o KEYTRUDA Sales Grew 22% to $20.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% o GARDASIL/GARDASIL 9 Sales Grew 22% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% - Full-Year 2022 GAAP EPS From Continuing Operations Was $5.71; Full-Year 2022 Non-GAAP EPS Was $7.48
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.